- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.05. | MANGOCEUTICALS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 01.04. | MANGOCEUTICALS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | MANGOCEUTICALS, INC. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 1 | SEC Filings | ||
| 17.03. | Mangoceuticals verklagt Technologie-Dienstleister auf 73 Millionen US-Dollar | 5 | Investing.com Deutsch | ||
| 17.03. | Mangoceuticals, Inc.: Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc. | 394 | GlobeNewswire (Europe) | Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals," the "Company," or "MangoRx"), a company focused on developing, marketing, and selling health... ► Artikel lesen | |
| 17.03. | MANGOCEUTICALS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 06.03. | Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds | 355 | GlobeNewswire (Europe) | Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine... ► Artikel lesen | |
| 23.02. | Mangoceuticals: Aktie steigt nach positiven Daten zu antiviralem Geflügel-Wirkstoff | 2 | Investing.com Deutsch | ||
| MANGOCEUTICALS Aktie jetzt für 0€ handeln | |||||
| 23.02. | Mangoceuticals, Inc.: Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study | 192 | GlobeNewswire (Europe) | Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine... ► Artikel lesen | |
| 19.02. | MANGOCEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.02. | MANGOCEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.01. | MANGOCEUTICALS, INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 13.01. | MANGOCEUTICALS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 14.11.25 | Mangoceuticals, Inc.: Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs | 2.283 | GlobeNewswire (Europe) | Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company") is issuing the following clarification regarding its press release issued earlier... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEALWELL AI | 0,478 | +0,53 % | HEALWELL AI: HEALWELL AI Announces Voting Results of 2026 AGSM | Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative... ► Artikel lesen | |
| SPINEWAY | 0,121 | 0,00 % | Spineway: First-quarter 2026 revenue | Ecully, April 30, 2026 - 6:00 p.m. First-quarter 2026 revenue High order volumeSlower-than-expected normalization of supply chains2026: growth trajectory confirmed In thousands of euros20262025Change... ► Artikel lesen | |
| ASENSUS SURGICAL | - | - | Karl Storz to fully integrate Asensus, discontinue Senhance, Luna robots | ||
| LIFEWARD | 7,660 | -2,42 % | Lifeward Ltd.: Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform | Veteran physician- medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience- mobility technologies, and metabolic disease... ► Artikel lesen | |
| IMUNON | 1,560 | 0,00 % | IMUNON announces executive transition: Josh Blacher appointed interim CFO as Jeffrey Church retires | ||
| NUWELLIS, INC | 3,090 | +1,31 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA92838G1090 Visionary Metals Corp. 25.06.2026 CA92838G2080 Visionary Metals Corp. 26.06.2026 Tausch 4:1US67113Y7022 Nuwellis... ► Artikel lesen | |
| INSPIRE MEDICAL SYSTEMS | 39,400 | +0,51 % | Inspire Medical: Freedom Capital startet Coverage mit Kaufempfehlung und verweist auf attraktive Bewertung | ||
| INSPIREMD | 0,635 | +2,42 % | InspireMD Inc.: InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures | MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced... ► Artikel lesen | |
| LOGICMARK | - | - | LogicMark, Inc.: Survey Exposes a Crisis of Avoidance in Family Caregiving | ||
| GT BIOPHARMA | 0,487 | -0,47 % | GT Biopharma, Inc.: GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors |
GTB-5550 is now the 3rd TriKE- to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation... ► Artikel lesen | |
| INOGEN | 5,950 | +5,31 % | Inogen Inc - S-8, Securities to be offered to employees in employee benefit plans | ||
| MYOMO | 0,893 | -2,40 % | MYOMO, INC. - 8-K, Current Report | ||
| INTELLIGENT BIO SOLUTIONS | 2,220 | -3,27 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry | Interference Study designed to validate system specificity in the presence of potentially interfering substances commonly encountered in real-world settings Company expects to complete the study by... ► Artikel lesen | |
| INCANNEX HEALTHCARE | 3,790 | +0,80 % | Incannex Healthcare: Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea | MELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative... ► Artikel lesen | |
| GLUCOTRACK | 0,315 | -1,16 % | GlucoTrack, Inc.: Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring... ► Artikel lesen |
MANGOCEUTICALS INC gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MANGOCEUTICALS INC finden Sie auf Wallstreet Online.